113 related articles for article (PubMed ID: 10360673)
1. Somatic mutation of PTEN in bladder carcinoma.
Aveyard JS; Skilleter A; Habuchi T; Knowles MA
Br J Cancer; 1999 May; 80(5-6):904-8. PubMed ID: 10360673
[TBL] [Abstract][Full Text] [Related]
2. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.
Kwabi-Addo B; Giri D; Schmidt K; Podsypanina K; Parsons R; Greenberg N; Ittmann M
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11563-8. PubMed ID: 11553783
[TBL] [Abstract][Full Text] [Related]
3. Genomic Deletion at
Poluri RTK; Audet-Walsh É
Front Oncol; 2018; 8():246. PubMed ID: 30009155
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of p53 and Pten promotes invasive bladder cancer.
Puzio-Kuter AM; Castillo-Martin M; Kinkade CW; Wang X; Shen TH; Matos T; Shen MM; Cordon-Cardo C; Abate-Shen C
Genes Dev; 2009 Mar; 23(6):675-80. PubMed ID: 19261747
[TBL] [Abstract][Full Text] [Related]
5. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
6. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers.
Koksal IT; Yasar D; Dirice E; Usta MF; Karauzum S; Luleci G; Baykara M; Sanlioglu S
Urol Int; 2005; 75(2):102-6. PubMed ID: 16123561
[TBL] [Abstract][Full Text] [Related]
7. Structural or functional defects of PTEN in urothelial cells lacking P53 drive basal/squamous-subtype muscle-invasive bladder cancer.
He F; Zhang F; Liao Y; Tang MS; Wu XR
Cancer Lett; 2022 Dec; 550():215924. PubMed ID: 36195293
[TBL] [Abstract][Full Text] [Related]
8. Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy.
Huan J; Grivas P; Birch J; Hansel DE
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326708
[TBL] [Abstract][Full Text] [Related]
9. Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications.
Minoli M; Kiener M; Thalmann GN; Kruithof-de Julio M; Seiler R
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784716
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer.
Osei-Amponsa V; Buckwalter JM; Shuman L; Zheng Z; Yamashita H; Walter V; Wildermuth T; Ellis-Mohl J; Liu C; Warrick JI; Shantz LM; Feehan RP; Al-Ahmadie H; Mendelsohn C; Raman JD; Kaestner KH; Wu XR; DeGraff DJ
Oncogene; 2020 Feb; 39(6):1302-1317. PubMed ID: 31636388
[TBL] [Abstract][Full Text] [Related]
11. Prothymosin-α enhances phosphatase and tensin homolog expression and binds with tripartite motif-containing protein 21 to regulate Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling in human bladder cancer.
Tsai YS; Jou YC; Tsai HT; Shiau AL; Wu CL; Tzai TS
Cancer Sci; 2019 Apr; 110(4):1208-1219. PubMed ID: 30719818
[TBL] [Abstract][Full Text] [Related]
12. PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance.
Russell L; Swanner J; Jaime-Ramirez AC; Wang Y; Sprague A; Banasavadi-Siddegowda Y; Yoo JY; Sizemore GM; Kladney R; Zhang J; Lehman NL; Ostrowski MC; Hong B; Caligiuri M; Yu J; Kaur B
Nat Commun; 2018 Nov; 9(1):5006. PubMed ID: 30479334
[TBL] [Abstract][Full Text] [Related]
13. miR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells.
Tsai TF; Lin JF; Chou KY; Lin YC; Chen HE; Hwang TI
Onco Targets Ther; 2018; 11():239-252. PubMed ID: 29379304
[TBL] [Abstract][Full Text] [Related]
14. Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.
Kulac I; Arslankoz S; Netto GJ; Ertoy Baydar D
Virchows Arch; 2018 Jun; 472(6):969-974. PubMed ID: 29368083
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.
Kashiwagi E; Inoue S; Mizushima T; Chen J; Ide H; Kawahara T; Reis LO; Baras AS; Netto GJ; Miyamoto H
Br J Cancer; 2018 Jan; 118(2):213-223. PubMed ID: 29123257
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Ross RL; McPherson HR; Kettlewell L; Shnyder SD; Hurst CD; Alder O; Knowles MA
BMC Cancer; 2016 Jul; 16():553. PubMed ID: 27465249
[TBL] [Abstract][Full Text] [Related]
17. The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN.
Egawa H; Jingushi K; Hirono T; Ueda Y; Kitae K; Nakata W; Fujita K; Uemura M; Nonomura N; Tsujikawa K
Sci Rep; 2016 Feb; 6():20574. PubMed ID: 26837847
[TBL] [Abstract][Full Text] [Related]
18. Identification of a hypoxia-regulated miRNA signature in bladder cancer and a role for miR-145 in hypoxia-dependent apoptosis.
Blick C; Ramachandran A; McCormick R; Wigfield S; Cranston D; Catto J; Harris AL
Br J Cancer; 2015 Aug; 113(4):634-44. PubMed ID: 26196183
[TBL] [Abstract][Full Text] [Related]
19. Genetic deletion and pharmacological inhibition of Akt1 isoform attenuates bladder cancer cell proliferation, motility and invasion.
Sabbineni H; Alwhaibi A; Goc A; Gao F; Pruitt A; Somanath PR
Eur J Pharmacol; 2015 Oct; 764():208-214. PubMed ID: 26148825
[TBL] [Abstract][Full Text] [Related]
20. Effect of PTEN Gene Mutations and Environmental Risk Factors on the Progression and Prognosis of Bladder Cancer.
Mashhadi R; Pourmand G; Mehrsai A; Pakdel S; Dialameh H; Ahmadi A; Salem S; Salimi E; Mahboubi R
Iran J Public Health; 2014 Jan; 43(1):56-61. PubMed ID: 26060680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
